Evotec SE (NASDAQ:EVO – Free Report) – Stock analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of Evotec in a note issued to investors on Thursday, April 25th. HC Wainwright analyst D. Tsao forecasts that the company will post earnings per share of ($0.10) for the year. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.23) per share. HC Wainwright also issued estimates for Evotec’s FY2025 earnings at $0.02 EPS, FY2026 earnings at $0.36 EPS and FY2027 earnings at $0.42 EPS.
Other research analysts also recently issued reports about the stock. Royal Bank of Canada upgraded shares of Evotec from a “sector perform” rating to an “outperform” rating in a research report on Thursday, January 18th. Deutsche Bank Aktiengesellschaft raised Evotec from a “hold” rating to a “buy” rating in a report on Friday, April 12th.
Evotec Stock Performance
Shares of EVO opened at $5.19 on Monday. The business’s fifty day moving average price is $7.16 and its 200 day moving average price is $8.55. Evotec has a 12-month low of $4.87 and a 12-month high of $13.49.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. Quadrant Capital Group LLC acquired a new stake in Evotec in the fourth quarter worth about $25,000. Optiver Holding B.V. boosted its holdings in shares of Evotec by 643.1% in the fourth quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock valued at $945,000 after acquiring an additional 69,936 shares in the last quarter. Finally, Mubadala Investment Co PJSC acquired a new position in shares of Evotec during the fourth quarter valued at approximately $53,931,000. Institutional investors own 5.81% of the company’s stock.
About Evotec
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health.
Featured Stories
- Five stocks we like better than Evotec
- Stock Dividend Cuts Happen Are You Ready?
- NXP Semiconductors Will Set a New High Soon: $300 in Sight
- Investing in large cap stocks: Diving into big caps
- Hilton Demonstrates Asset Light is Right for Investors
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
